Skip to content

Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing

A Pre-market, Open-label Feasibility, Prospective, Single-arm Multicenter Feasibility Investigation of Hearing Performance Using the CI632 in Adults With Low-frequency Residual Hearing.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04741009
Enrollment
10
Registered
2021-02-05
Start date
2021-12-16
Completion date
2025-06-16
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-Frequency Residual Hearing, Sensorineural Hearing Loss

Brief summary

The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.

Interventions

DEVICECI632 Slim Modiolar Electrode

Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode

Sponsors

Cochlear
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

1. 18 years-of-age or older at the time of surgery. 2. Low-frequency threshold at 500 Hz ≤ 50 dB HL and high-frequency pure-tone average (PTA), 2000-8000 Hz ≥ 65 dB HL in the ear to be implanted. 3. Pure-tone average (PTA) (0.5k, 1k, 2k Hz) \> 30 dB HL in the contralateral ear. 4. CNC word recognition scores (mean of two lists) ≤ 60% in the ear to be implanted and ≤ 80% in the contralateral ear. 5. English spoken as a primary language. 6. Willing and able to provide written informed consent.

Exclusion criteria

1. Individuals greater than or equal to 70 years at the time of surgery. 2. Duration of severe to profound sensorineural hearing loss \> 20 years per self-report. 3. Onset of sensorineural hearing loss, for the purpose of this study, prior to 5 years-of-age. 4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range of 250 through 1000 Hz in the ear to be implanted. 6. Hearing loss of neural or central origin. 7. Diagnosis of Auditory Neuropathy. 8. Active middle-ear infection. 9. Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator. 10. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the device and/or procedure, as determined by the Investigator. 11. Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator. 12. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator. 13. Investigator site personnel directly affiliated with this study and/or their immediate family (spouse, parent, child, or sibling). 14. Cochlear employees or employees of a Contract Research Organization (CRO) or contractors engaged by Cochlear for the purposes of this investigation. 15. Currently participating, or has participated in the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.

Design outcomes

Primary

MeasureTime frameDescription
To Characterize Hearing Performance of the CI632 in an Adult Population Under Expanded Indications for Use.14 months (12 months postactivation)To characterize hearing performance of the CI632 using the Consonant-Nucleus-Consonant (CNC) monosyllabic word recognition test in quiet (unilateral). Two CNC word lists will be administered at a level equal to 60 dBA in the sound field and scored as a total number of words correct, expressed as a percentage correct.

Countries

United States

Baseline characteristics

Characteristic
Age, Continuous61.3 years
STANDARD_DEVIATION 9.8
Race/Ethnicity, Customized
Non-Hispanic
10 Participants
Race/Ethnicity, Customized
White
10 Participants
Region of Enrollment
United States
10 Participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
2 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 10
other
Total, other adverse events
7 / 10
serious
Total, serious adverse events
0 / 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026